Menstrual Suppression in the Myelosuppressed: A Retrospective Cohort Study

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Menstrual Suppression in the Myelosuppressed: A Retrospective Cohort Study

header-info

Jun, 02, 2023

In a cohort of 90 adolescent and young adult female patients treated with myelosuppressive therapies and diagnosed with either Hodgkin or non-Hodgkin lymphoma, acute myeloid leukemia, or sarcoma, researchers discovered that 77.8% of patients experienced menstrual suppression. Despite this, researchers identified different practice patterns between pediatric and adult oncologists, resulting in patients being prescribed a wide variety of different agents.

Access the full article to read more here.